Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Figure 6 Multimodal treatment of locally advanced gastric cancer according to the molecular profiling.
Extended lymphadenectomy contraindicated if para-aortic nodal involvement with bulky extragastric nodes or remaining stable after neoadjuvant chemotherapy. 1Indicate a possible role of immunotherapy in combination with chemotherapy in a neoadjuvant setting. MSI: Microsatellite instable; MSS: Microsatellite stability; EMT: Epithelial-mesenchymal transition; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; HER: Human epidermal growth factor receptor; HIPEC: Hyperthermic intraperitoneal chemotherapy.
- Citation: Carbone L, Marrelli D, Barbato B, Visani A, Corso G, Roviello F. Specific molecular signature redefines the role of posterior and para-aortic (D2 plus) lymphadenectomy in gastric cancer: Rethinking surgical indications. World J Clin Oncol 2026; 17(11): 126700
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/126700.htm
- DOI: https://dx.doi.org/10.5306/wjco.126700